Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (174,244)	$ (178,625)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	47	24
Amortization of debt discount	195	64
Change in fair value of contingent consideration liability - related parties	(173)	1,133
Change in fair value of short term notes receivable - related parties		(718)
Change in fair value of convertible promissory notes		16,974
Change in fair value of derivative liability	41	150
Change in fair value of warrant liability	(87)
Unrealized loss on other investments held at fair value	12,346
Unrealized gain on other investments		(19,856)
Other assets	(5,973)
Gain on dilution of equity method investment	(16,923)
Loss on conversion of convertible notes	513
Gain on consolidation of a variable interest entity	(3,543)
Loss on asset acquisition of a variable interest entity		504
Losses from investments in equity method investees	58,555	76,507
In-process research and development expense	15,480	12,020
Stock-based compensation expense	63,362	67,158
Unrealized foreign exchange gains	(11,346)	(155)
Other	43	(96)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(9,699)	(1,150)
Accounts payable	2,300	1,704
Accrued liabilities	5,756	3,896
Deferred revenue	12
Net cash used in operating activities	(63,246)	(20,766)
Cash flows from investing activities
Purchases of property and equipment	(173)	(59)
Capitalized internal-use software development costs	(955)
Cash acquired in asset acquisitions, net	47	276
Cash paid for asset acquisitions, net	(1,000)
Cash paid for equity method investments	(52,937)	(2,088)
Cash paid for other investments	(11,312)	(23,920)
Cash paid for other investments held at fair value	(12,346)
Purchases of short - term notes receivable - related party		(226)
Purchases of long term notes receivable		(1,916)
Loans to related parties	(2,600)
Other	0	(338)
Net cash used in investing activities	(81,276)	(28,271)
Cash flows from financing activities
Proceeds from issuance of common stock	409,884	82,439
Cash paid for common stock issuance costs	(12,350)	(1,314)
Purchase of noncontrolling interest	0	0
Cash paid for deferred offering costs		(696)
Proceeds from issuance of share option awards	534
Proceeds from sale of investment	2,417
Proceeds from issuance of convertible promissory notes - related parties	0	1,022
Proceeds from issuance of convertible promissory notes	0	30,437
Proceeds from the issuance of convertible promissory notes (including proceeds from a related party convertible promissory note of $0.3 million for 2020)	1,588	1,044
Exercise of stock options	935	120
Proceeds from conversion of convertible notes to common stock	6,854
Net cash provided by financing activities	409,862	113,052
Effect of foreign exchange rate changes on cash	(320)	3,169
Net increase (decrease) in cash and cash equivalents	265,020	67,184
Cash and cash equivalents – beginning of the period	97,246	30,062
Cash and cash equivalents – end of the period	362,266	97,246
Supplemental disclosures of non-cash investing and financing information:
Common stock issuance costs in accounts payable	0	94
Common stock issuance costs in accrued liabilities		3,819
Conversion of short term notes receivable for other investments	0	9,003
Conversion of Other Investments into Equity Method Investments	0	53,101
Deferred offering costs in accounts payable		358
Deferred offering costs in accrued liabilities	0	468
Fair value of noncontrolling interests issued in connection with asset acquisitions	4,761	12,312
Fair value of noncontrolling interests issued in connection with consolidation of a VIE	392
Fair value of redeemable noncontrolling interests issued in connection with consolidation of a VIE	2,555
Issuance of common shares in connection with the conversion of convertible promissory notes	0	50,059
Issuance of subsidiary shares in connection with a stock purchase agreement	0	120
Issuance Of Subsidiary Shares In Connection With The Conversion Of Convertible Notes	3,258	0
Exercise of Hurdle Share Option Plan award	527	0
Issuance of derivative instrument related to convertible promissory notes	$ 646	$ 364